Short summary
Introduction 40
Vaccination is a powerful strategy in the fight against infectious disease, including virus 41 infection. Indeed, vaccination led to the global eradication of smallpox and is higly protective 42 against some viruses including measles virus and yellow fever virus. However, the 43 development of vaccines inducing long-lasting and broadly effective protection has been 44 difficult for other viruses such as human immunodeficiency virus (HIV) and influenza A virus 45 (IAV), highlighting the need for new vaccination strategies (Rappuoli et al., 2011) . 46
Successful vaccines induce potent adaptive immune responses. Prophylactic vaccine-mediated 47
protection against most virus infections is thought to be predominantly due to induction of 48 antiviral antibody responses that prevent or rapidly control subsequent infection. Antibody 49 responses limit virus infection and spread through several mechanisms (Pelegrin et al., 2015) . 50
Neutralising antibodies directly bind virus particles and prevent them from infecting cells. Pyrophosphatase/Phosphodiesterase 1 (ENPP1), an enzyme degrading extracellular ATP and 107 cGAMP (Carozza et al., 2019; Li et al., 2014) . Indeed, when injected intra-muscularly, the 108 concentration of cGAMP at the inoculation site decreases rapidly, resulting in a sub-optimal 109 adjuvant effect (Wang et al., 2016) . 110
We and others previously showed that cGAMP is packaged into nascent viral particles as they 111 bud from the membrane of an infected cell (Bridgeman et al., 2015; Gentili et al., 2015) . Upon 112 virus entry into newly infected cells, cGAMP is released into the cytosol and directly activates 113 STING. Building on this observation, we hypothesised that inclusion of the adjuvant cGAMP 114 in viral vaccine vectors may enhance their immunogenicity by targeting adjuvant and antigen 115 to the same cell and by protecting cGAMP from degradation in the extracellular environment. 116
Indeed, using HIV-derived viral-like particles (VLPs), we found that the presence of cGAMP 117
within VLPs enhanced adaptive immune responses to VLP antigens. Antigen-specific CD4 and 118 CD8 T cell responses were augmented, as well as neutralising antibody production. The latter 119 was accompanied by an increase in Tfh cells in draining lymph nodes. cGAMP-loaded VLPs 120 containing the IAV haemagglutinin protein induced neutralising antibodies and conferred 121 protection against development of severe disease after challenge with live IAV. These results 122 highlight the utility of cGAMP loading as a strategy to boost the immunogenicity of viral 123 vaccine vectors. 124
Results 125
cGAMP-loading of HIV-derived VLPs 126
HIV-derived viral vectors and VLPs are routinely produced in the cell line HEK293T by 127 transfection of plasmids encoding viral components (Milone and O'Doherty, 2018) . Here, we 128 generated VLPs by using plasmids expressing the HIV-1 capsid protein Gag fused to GFP 129 (Gag-GFP) and the Vesicular Stomatitis Virus envelope glycoprotein (VSV-G). The resulting 130
VLPs consist of a Gag-GFP core and a lipid membrane derived from the producer cell that is 131 spiked with VSV-G proteins. Of note, these VLPs do not contain viral nucleic acid and can 132 therefore not replicate in the host (Deml et al., 2005) . Additional over-expression of cGAS in 133 the VLP producer cells results in its activation, presumably by the transfected plasmid DNA, 134
and in the presence of cGAMP in the cytosol. It is noteworthy that HEK293T cells do not 135 express STING (Burdette et al., 2011) ; therefore, cGAS-overexpressing VLP producer cells do 136 not respond to the presence of cGAMP. cGAMP is then packaged into the nascent viral 137 particles, which are released as cGAMP-loaded VLPs (hereafter cGAMP-VLPs; Fig 1A) . As a 138 control, we produced VLPs that do not contain cGAMP (Empty-VLPs) by using a catalytically 139 inactive version of cGAS. 140
To assess the efficiency of cGAMP incorporation into our VLPs, we extracted small molecules 141 from VLPs as previously described (Mayer et al., 2017) . cGAMP in the extract was then 142 quantified by ELISA. While Empty-VLPs did not contain detectable levels of cGAMP, 143 cGAMP-VLPs contained between 55 and 90 ng cGAMP per 10 6 infectious units (IU) of VLPs 144 (Fig 1B) . We then assessed the infectivity of the VLPs and found cGAMP-VLPs and Empty-145
VLPs to be equally infective (Fig 1C) . To confirm that cGAMP-VLPs trigger an IFN-I 146 response, supernatant from the STING-positive HEK293 cells used in the infectivity assay was 147 transferred to a reporter cell line expressing firefly luciferase under the interferon-sensitive 148 response element (ISRE) promoter (Bridgeman et al., 2015) . At similar infection rates, 149 cGAMP-VLPs induced IFN-I production while Empty-VLPs did not (Fig 1C) . Taken together, 150 these results show that cGAMP can be efficiently packaged into VLPs consisting of HIV-1 151
Gag-GFP and the VSV-G envelope. 152
153
Immunisation with cGAMP-VLPs induces higher and more polyfunctional CD4 and CD8 154
T cell responses compared to Empty-VLPs 155
To test whether cGAMP-VLPs induce a better immune response than Empty-VLPs in vivo, we 156 injected C57BL/6 mice intramuscularly with 10 6 infectious units of cGAMP-VLPs or Empty-157
VLPs or, as a control, PBS. We first assessed CD4 T cell responses in the spleen 14 days after 158 immunisation. As we were unable to identify a specific peptide epitope within HIV Gag 159 recognised by CD4 T cells in H-2 b mice, we used bone-marrow derived myeloid cells 160 (BMMCs) pulsed with cGAMP-VLPs for evaluation of antigen-specific CD4 T cell responses. 161
We co-cultured these cells with splenocytes for six hours before assessing IL-2, IFNg and 162
TNFa production by CD4 T cells by intracellular cytokine staining (ICS). Compared to mice 163
immunised with Empty-VLPs, we observed 2.7-fold increased frequencies of CD4 T cells 164 producing each of these cytokines in response to VLP-pulsed BMMCs in mice immunised with 165 cGAMP-VLPs (Fig 2A, gating strategy and exemplary FACS plots in Fig S1A) . Moreover, 166 cGAMP enhanced the proportion of cells that were able to co-produce two or all three cytokines 167 (Fig 2B; 2.1-and 3.7-fold increases, respectively). 168
We next assessed CD8 T cell responses following immunisation. We screened a panel of 169 overlapping 15-mer peptides spanning the HIV-1 Gag sequence and identified a peptide that 170 stimulated an IFNg response in cells from spleen in IFNg ELISPOT assays (peptide p92; Fig  171   S2A-B) . We then used NetMHCpan 3.0 (http://www.cbs.dtu.dk/services/NetMHCpan-3.0/ 172 (Nielsen and Andreatta, 2016)) to predict the optimal epitope sequence recognised within p92, 173
and identified a 9-mer peptide (SQVTNSATI, termed HIV-SQV) that triggered T cell 174 recognition more efficiently than the original 15-mer peptide (Fig S2C-D) . This 9-mer peptide 175 was also reported to constitute an immunodominant HIV-1 Gag epitope in H-2 b mice in a prior 176 study (Holechek et al., 2016) . The HIV-SQV peptide was used for all subsequent analyses of 177 VLP-elicited CD8 T cell responses. We evaluated responses to the HIV-SQV peptide by IFNg 178 ELISPOT assay and showed that, when compared to Empty-VLPs, cGAMP-VLPs induced a 179 modest but significant increase in the magnitude of the response (Fig 2C, 1.7-fold increase) . 180
To assess whether cGAMP-loading of VLPs also enhanced the polyfunctionality of the 181 responding CD8 T cells, we stimulated splenocytes for six hours and stained for upregulation 182 of CD107a (LAMP-1), a degranulation marker, and for the production of IFNg, TNFa and IL-183 2 by ICS. Paralleling the results from the ELISPOT assay, CD8 T cells from mice immunised 184 with cGAMP-VLPs showed a modest but significant increase in the frequency of cells 185 upregulating CD107a (1.6-fold increase) and/or producing IFNg (2-fold) and/or TNFa (1.9-186 fold) (Fig 2D, gating strategy and exemplary FACS plots in Fig S1B) . Furthermore, cGAMP 187 enhanced the proportion of CD8 T cells that were able to co-produce two of the cytokines 188 evaluated (Fig 2E; 1.9-fold increase). One month after immunisation, mice were challenged with vVK1, and five days after infection 194 virus load in the ovaries was assessed by plaque assay. We observed no weight loss over the 195 course of the infection (Fig S3A) . Immunisation with both VLPs reduced vVK1 load, and 196 cGAMP-VLP immunised mice showed a slight but non-significant increase in protection 197 compared to animals immunised with Empty-VLPs (Fig S3B) . days after immunisation, indicating antibody class-switching (Fig 3A and Fig S4A) . 208
Interestingly, immunisation with cGAMP-VLPs induced stronger anti-VLP antibody responses 209 compared to the Empty-VLP immunised group, with statistically significant differences being 210 observed in IgG2a/c, IgG2b and IgM levels. We also detected IgG antibodies targeting the 211 VSV-G envelope, and IgG1, IgG2a/c and IgG2b titres were higher in the cGAMP-VLP 212 immunised group (Fig 3B) . Titres of antibodies recognising the intracellular antigen HIV-Gag 213 were low or undetectable, but a similar trend was observed for a higher-magnitude response in 214 the cGAMP-VLP immunised group (Fig 3C and S4A) . 215
To test whether the anti-VLP antibodies were neutralising, we assessed the in vitro 216 neutralisation capacity of sera using a VSV-G pseudotyped HIV-1-based lentivector 217 expressing GFP (Fig 3D) . The effect of pre-incubation with serum samples on the infectivity 218 of the HIV-1-GFP virus was measured by monitoring GFP expression in HEK293 cells (Fig  219   S4B -C). Although immunisation with both cGAMP-VLPs and Empty-VLPs induced 220 neutralising antibodies, this response was stronger when cGAMP was present within the VLPs, 221 and sera from cGAMP-VLP immunised mice showed a 2.5-times higher half maximal 222 inhibitory concentration (Fig 3E-F) . In summary, immunisation with cGAMP-VLPs induced 223 an increased antibody response that targeted proteins from total VLP lysates including the 224 VSV-G envelope protein. Moreover, cGAMP-loading enhanced production of virus 225 neutralising antibodies. 226
Incorporation of cGAMP into VLPs increases the CD4 Tfh cell response 228
To gain insight into how immunisation with cGAMP-VLPs resulted in an increased antibody 229 response, we investigated B and T cell populations in inguinal lymph nodes that drain the 230 injection site. As CD4 T cell responses were increased in the spleens of cGAMP-VLP 231
immunised mice, we first tested whether follicular CD4 T cell numbers were elevated in 232 lymphoid tissues draining the immunisation site. We identified follicular CD4 T cells as 233
hi CXCR5 hi and subdivided them into Tfh and Tfr cells by analysing FoxP3, 234 which is expressed in Tfr cells (Fig 4A) . Immunisation with VLPs led to an increase in the 235 proportion of follicular T cells within the CD4 T cell population in the draining lymph node 236 (Fig 4A-B) . This was due to an expansion of Tfh cells, as the latter increased significantly in 237 frequency after VLP immunisation, whereas Tfr frequencies within CD4 T cells remained 238 unaltered. As a consequence of this, there was a profound shift in the Tfh:Tfr ratio in VLP-239 immunised as compared to control mice (Fig 4C) . Importantly, the increase in Tfh cells was 240 more pronounced in cGAMP-VLP immunised mice compared to Empty-VLP injected animals 241
To assess the impact of this increased Tfh response on B cell responses, we first gated on GC 243 B cells (B220 + IgD -CD95 + GL7 + cells; Fig 4D) . Immunisation with VLPs induced a robust GC 244 B cell response, with no difference being observed in the frequencies of GC B cells in cGAMP-245 VLP and Empty-VLP groups at the day 14 time-point analysed ( Fig 4E) . We next evaluated 246 the generation of antibody-secreting cells (ASCs) by antigen-specific B cell ELISPOT assay 247 on cells from both draining lymph nodes and spleens 14 days after immunisation. VLP-specific 248
ASCs were detected in the lymph nodes of mice injected with both cGAMP-VLPs and Empty-249
VLPs (Fig 4F) . In the spleen, VLP-specific ASCs were also observed in cGAMP-VLP 250 immunised animals, but not in Empty-VLP immunised animals ( Fig 4F) . Taken suggesting that the presence of HA did not affect the incorporation of cGAMP into the VLPs 271 (Fig S5C) . 272
Next, we immunised mice with HA-VLPs. Two weeks after immunisation, sera were analysed 273 for neutralising antibodies using a micro-neutralisation assay. In brief, a single cycle IAV 274 expressing eGFP and PR8 HA was pre-incubated with sera and its infectivity was then 275 monitored using MDCK-SIAT1 cells (Powell et and VLPs were produced by co-transfecting plasmids encoding Gag-eGFP and the VSV-G 394 envelope (pGag-EGFP and pCMV-VSV-G, respectively) at a ratio of 2:1. VLPs were loaded 395 with cGAMP by co-transfecting at the same time a plasmid encoding mouse cGAS WT 396 (pcDNA3-Flag-mcGAS). Empty-VLPs were produced as control by co-transfecting a 397 catalytically inactive mouse cGAS (cGAS AA; pcDNA3-Flag-mcGAS-G198A/S199A). One 398 day after transfection, the medium was changed. reporter cells to assess IFN-I production in response to cGAMP incorporated in VLPs as 425 described previously (Bridgeman et al., 2015) . After 24 hours of incubation with supernatants, 426 expression of the ISRE-Luc reporter was assessed using the One-Glo luciferase assay system. 427
Small molecular extracts were prepared from VLPs as described (Mayer et al., 2017) . Briefly, 428 2x10 6 IU of ultra-centrifuged VLPs resuspended in PBS were lysed in X-100 Buffer (1mM 429 NaCl, 3mM MgCl2, 1mM EDTA, 1% Triton X-100, 10mM Tris pH7.4) by adding 1/10 volume 430 of 10X buffer for 20 minutes on ice while vortexing regularly. After centrifugation at 1,000g 431 for 10 minutes at 4°C, supernatants were treated with 50U/mL of benzonase for 45 minutes on 432 ice. Samples were then extracted with phenol-chloroform, and the aqueous phase was then 433 transferred to Amicon Ultra 3K filter columns. After filtering by centrifugation at 14,000g for 434 30 minutes at 4°C, samples were dried in a SpeedVac and resuspended in 200µL of water. 435 cGAMP was quantified using the 2'-3' cGAMP ELISA kit following manufacturer's 436
instructions. 437 438

IAV 439
The Influenza virus H1N1 A/Puerto Rico/8/1934 (Cambridge) (PR8) and the non-replicating 440 S-FLU vector expressing eGFP (S-eGFP) were generated as previously described (Powell et The TCID50 was determined by infecting MDCK-SIAT1 or MDCK-PR8 cells with a ½-log 453 dilution series of viruses in VGM for one hour in eight replicates using 96-well flat-bottom 454 plates. Next, 150µl per well of VGM with TPCK-treated trypsin (1 µg/mL) was added and 455 cells were further incubated for 48 hours at 37°C. The PR8 virus and the S-eGFP vector were 456 quantified by Nucleoprotein (NP) staining and eGFP expression respectively and TCID50 was 457 calculated using the method of Reed and Muench (Reed and Muench, 1938) . 458
459
Vaccinia virus 460
Stocks of the vaccinia virus expressing HIV-1 HXB.2 Gag (vVK1) were produced by growth 461 in 143TK-cells, and infectious virus titers were determined by plaque assay (Borrow et For IAV challenge, blood samples were acquired two weeks after immunisation for evaluation 473 of the serum antibody response. Mice were then challenged a month after immunisation via the 474 intranasal route with 10,000 TCID50 of PR8 diluted in 50µL VGM under inhalation isoflurane 475 anaesthesia. Weight was monitored daily and mice were culled by inhalation of carbon dioxide 476 and cervical dislocation when body weight loss approached the humane end-point of 20%. 477
For vaccinia virus challenge, mice were infected via the intra-peritoneal route with 10 6 PFU 478 vVK1 in 100µL PBS. Weight was monitored daily for five days. Animals were then culled by 479 inhalation of carbon dioxide and cervical dislocation, and ovaries were collected for virus 480
titration. 481 482
Analysis of T cell responses by ICS and ELISPOT 483
Splenocytes were obtained by separating spleens through a 70µm strainer, and were then 484 treated with red blood cell lysis buffer for 5 minutes, washed and resuspended in RPMI 485 supplemented with 2% Human serum, 2mM L-Glutamine, 1% PenStrep (R2). 486
For ELISPOT assays, splenocytes were seeded in R2 at a density of 1.5x10 5 
cells per well on 487
ELISPOT plates pre-coated with anti-IFNg detection antibody. Cells were either non-treated 488 or treated with 2µg/mL HIV-1 Gag peptide or with 10ng/mL PMA and 1µg/mL ionomycin as 489 a control, and incubated for 48 hours at 37°C before detection according to the manufacturer's 490 
instructions (Mouse IFNg ELISPOT BASIC (ALP) kit). 491
Vaccinia virus plaque assay 571
Ovaries collected in D0 (DMEM, 1% PenStrep) were homogenised using glass beads in screw 572 cap tubes in a homogeniser (two cycles at speed 6.5 for 30 seconds). Samples were then placed 573 on ice for 1-2 minutes and homogenisation was repeated. Samples were then subjected to three 574 freeze-thaw cycles between 37°C and dry ice and sonicated three times for 30 seconds with 30 575 second intervals on ice. Supernatants containing virus were collected in new tubes after 576 centrifugation at 10,000 rpm for 3 minutes at 4°C. 577 143B cells were seeded in 12 well plates at a density of 0.25x10 6 cells per well in 1mL D10. 578
The next day, log serial dilutions of virus-containing samples were prepared in D0. Supernatant 579 was replaced with 550µl of diluted virus-containing samples and incubated for 2 hours at 37°C, 580 
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A-B. Immunisation with cGAMP-VLPs enhances VLP-specific CD4 T cell responses. 645
BMMCs from C57BL/6 mice were pulsed overnight with cGAMP-VLPs and used to stimulate 646 and (E). Statistical analyses were performed using a 2-way ANOVA followed by Tukey's 659 multiple comparisons test. In (A), (C) and (D), data were blocked on experiments. ns p≥0.05; 660 *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 661 Horizontal lines show the mean. x=sample below limit of detection (LOD). 774
Statistical analyses were done using a 2-way ANOVA followed by Tukey's multiple 775 comparisons test. ns p≥0.05; **p<0.01. 776 
